Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Stéphane Culine et al.|New England Journal of Medicine|2017Cited by 3.4k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Petros Grivas, Se Hoon Park et al.|New England Journal of Medicine|2020Cited by 1.5k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, Joaquim Bellmunt et al.|Annals of Oncology|2019Cited by 484
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, Dana E. Rathkopf et al.|Journal of Clinical Oncology|2023Cited by 317
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-UpThomas Powles, Petros Grivas, Se Hoon Park et al.|Journal of Clinical Oncology|2023Cited by 210